The global pharmacovigilance market is projected to grow from USD 8.91 billion in 2025 to USD 24.69 billion by 2035, at a CAGR of 10.34%. Growth is driven by stringent regulatory requirements, increased adverse drug reaction incidents, and pharmaceutical industry expansion into emerging markets. The U.S. market alone is expected to reach USD 9.48 billion by 2035. Phase IV post-market surveillance and contract outsourcing services dominate the market segments.

Despite a 35% stock decline over the past six months due to competition concerns, Veeva Systems remains a solid long-term buy. The company's specialized cloud services for life sciences companies create strong switching costs and competitive advantages. With a goal to double revenue to $6 billion by 2030 and a history of meeting targets, Veeva is well-positioned to capitalize on the expanding life sciences industry.

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.

Three major software stocks—Okta, Veeva Systems, and Guidewire Software—have announced significant share buyback programs following sharp declines in their stock prices. Okta authorized a $1 billion buyback after falling 28% from its 52-week high, Veeva announced its first-ever $2 billion program after dropping 21%, and Guidewire launched a $500 million buyback following a 29% decline. These announcements signal management confidence that their shares are undervalued, with analysts seeing the most upside potential in Guidewire.

The Electronic Clinical Outcome Assessment (eCOA) Solutions Market is expected to grow from USD 1.57 billion in 2023 to USD 5.64 billion by 2032, with a 15.3% CAGR, driven by digital transformation in clinical research and increasing regulatory compliance requirements.

The article highlights Netflix and Veeva Systems as promising growth stocks for investors, discussing their market positions, recent performance, and potential for future expansion in streaming and cloud computing sectors.

Wall Street rebounded on Friday with markets gaining around 1%, as investors speculated about potential Federal Reserve interest rate policy changes. Notable stock movements included gains for Cava and WillScot, while Elastic and Veeva experienced declines following earnings reports.

U.S. stock futures showed mixed performance after Thursday's sell-off, with markets digesting a stronger-than-expected September jobs report and potential Federal Reserve interest rate decisions. Several companies reported earnings, with varied market reactions.

HealthEx, a health data rights management platform, has appointed Jeremy Schwarz as Chief Commercial Officer to accelerate growth and drive patient-directed data exchange across healthcare ecosystems.

The article highlights two growth stocks, Veeva Systems and Spotify Technology, which have outperformed the market in 2025 and show potential for continued growth through strategic innovations and market positioning.

Baltimore-based Brown Capital Management sold 861,020 shares of Vericel Corporation for approximately $31 million in Q3 2025, reducing its stake while the biotech company reported strong quarterly revenue growth of 17%.

Veeva Systems is a software company providing AI-enhanced solutions for pharmaceutical companies, offering tools for drug discovery, clinical trials, and sales processes. The company shows strong growth, profitability, and strategic positioning in integrating AI into healthcare technology.